Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
Why now
Thesis: Capital raise dilutes holders ahead of trial data
Catalyst to watch: Pricing terms and use of proceeds
Main risk: Dilution and convertible overhang
Why it matters
Equity and convertible offerings dilute existing holders and signal capital need for a clinical-stage biotech.
Details
SAN DIEGO, Sept. 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention to offer, subject to market and other...
Sources
- prnewswire · 2026-09-23 20:32 UTC